A5076723441- Acute Ischemic Stroke Management
- Stroke Rehabilitation and Recovery
- Cerebrovascular and Carotid Artery Diseases
- Dementia and Cognitive Impairment Research
- Health Systems, Economic Evaluations, Quality of Life
- Alzheimer's disease research and treatments
- Traumatic Brain Injury and Neurovascular Disturbances
- Venous Thromboembolism Diagnosis and Management
- Ethics in Clinical Research
- Traumatic Brain Injury Research
- Thermal Regulation in Medicine
- Retinal and Optic Conditions
- Intracerebral and Subarachnoid Hemorrhage Research
- Cerebral Venous Sinus Thrombosis
- Cholinesterase and Neurodegenerative Diseases
- Hospital Admissions and Outcomes
- Atrial Fibrillation Management and Outcomes
- Healthcare Systems and Practices
- Clinical practice guidelines implementation
- Cardiac Arrest and Resuscitation
- Fatty Acid Research and Health
- Neonatal and fetal brain pathology
- Ultrasound and Hyperthermia Applications
- Ginkgo biloba and Cashew Applications
- Meta-analysis and systematic reviews
University of Southern California
2016-2025
Autism Research Institute
2016-2025
University of California, Irvine
2024
Indiana University – Purdue University Indianapolis
2024
University of Pennsylvania
2012-2024
Janssen (United States)
2024
Indiana University School of Medicine
2024
Brigham and Women's Hospital
2024
Harvard University
2024
University of Virginia
2024
There are no US Food and Drug Administration-approved therapies for neonatal seizures. Phenobarbital phenytoin frequently fail to control concerns about the safety of seizure medications in developing brain. Levetiracetam has proven efficacy an excellent profile older patients; therefore, there is great interest its use neonates. However, randomized studies have not been performed. Our objectives were study levetiracetam compared with phenobarbital as a first-line treatment seizures.The was...
Therapeutic hypothermia is a potent neuroprotectant approved for cerebral protection after neonatal hypoxia-ischemia and cardiac arrest. acute ischemic stroke safe feasible in pilot trials. We designed study protocol to provide safer, faster therapeutic patients.Safety procedures 4°C saline infusions cooling were added the ICTuS trial (Intravascular Cooling Treatment of Stroke) protocol. A femoral venous intravascular catheter intravenous recombinant tissue-type plasminogen activator...
Telemedicine can disseminate vascular neurology expertise and optimize recombinant tissue plasminogen activator (rt-PA) use for acute ischemic stroke in rural underserved communities. The purpose of this study was to prospectively assess whether telemedicine or telephone superior decision-making.
Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline participants with preclinical Alzheimer disease. Preliminary analyses suggested dose-related worsening and neuropsychiatric adverse events (AEs).To report efficacy, safety, biomarker findings trial, both on off atabecestat treatment, focus potential recovery of effects cognition behavior.Randomized, double-blind, placebo-controlled, phase 2b/3 study conducted from November...
<h3>Importance</h3> The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment presymptomatic stages, which will require biomarker testing disclosure. <h3>Objective</h3> To assess the short-term psychological outcomes disclosing amyloid positron emission tomography results older adults who did not have cognitive impairment. <h3>Design, Setting, Participants</h3> This observational study included participants were screening for a multisite randomized...
Abstract INTRODUCTION The long‐term implications of disclosing Alzheimer's disease (AD) biomarker information to cognitively unimpaired individuals are unknown. METHODS We compared participants who disclosed their elevated amyloid imaging result in a preclinical AD trial those not and enrolled an observational cohort that underwent parallel assessments. Our primary outcome was score > 0 on the Columbia Suicidality Severity Rating Scale (CSSRS) at any visit; we also considered suicidal...
<b><i>Objective:</i></b> To determine the effect of idebenone on rate decline in Alzheimer's disease (AD). <b><i>Methods:</i></b> A 1-year, multicenter, double-blind, placebo-controlled, randomized trial was conducted. Subjects were over age 50 with a diagnosis probable AD and had Mini-Mental State Examination (MMSE) scores between 12 25. treated 120, 240, or 360 mg tid, each which compared placebo. Primary outcome measures Disease Assessment Scale–Cognitive Subcomponent (ADAS-Cog) Clinical...
<i>Background:</i> Prior epidemiological work has shown higher mortality in ischemic stroke patients admitted on weekends, which been termed the ‘weekend effect’. Our aim was to assess patient outcomes order determine significance of effect’ at 2 comprehensive centers. <i>Methods:</i> Consecutive were identified using prospective databases. Patients categorized into 4 groups: intracerebral hemorrhage (ICH group), strokes not treated with IV t-PA (intravenous tissue...
To compare the effect of disc size and disease severity on Heidelberg Retina Tomograph (HRT) Glaucoma Probability Score (GPS) Moorfields Regression Analysis (MRA) for discriminating between glaucomatous healthy eyes.Ninety-nine eyes with repeatable standard automated perimetry results showing damage 62 normal were included from longitudinal Diagnostic Innovations in Study (DIGS). The visual field defects ranged early to severe (average [95% CI] pattern deviation [PSD] was 5.7 [5.0-6.5] dB)....
<h3>Objective:</h3> Alzheimer disease (AD) dementia clinical trials require 2 participants: a patient and study partner. We assessed the prevalence of partner types how these associate with patient-related outcome measures. <h3>Methods:</h3> Retrospective analyses 6 Alzheimer’s Disease Cooperative Study (ADCS) randomized were conducted. partners categorized as spouse, adult child, or other. Prevalence type associations between trial outcomes including completion placebo decline on...
<b><i>Background and Purpose:</i></b> Previous studies have found mortality among ischemic stroke patients to be higher on weekends. We sought evaluate whether weekend admission was associated with worse outcomes in a large comprehensive center (CSC) cohort. <b><i>Methods:</i></b> Consecutive presenting within 6 h of symptom onset were identified using the 8 CSC SPOTRIAS (Specialized Programs Translational Research Acute Stroke) database....
Mild traumatic brain injury (mTBI) is a common for service members in recent military conflicts. There insufficient evidence of how best to treat the consequences mTBI. In randomized, clinical trial, we evaluated efficacy telephone-delivered problem-solving treatment (PST) on psychological and physical symptoms 356 post-deployment active duty from Joint Base Lewis McChord, Washington, Fort Bragg, North Carolina. Members with medically confirmed mTBI sustained during deployment Iraq...
Many factors contribute to inadequate diversity in Alzheimer disease (AD) clinical trials. We evaluated eligibility rates among racial and ethnic groups at US sites large global multisite trials early AD.
Background and Purpose— The American Stroke Association guidelines emphasized the need for further high-quality studies that assess agreement by radiologists nonradiologists engaged in emergency telestroke assessments decision-making. Therefore, objective of this study was to determine level baseline brain CT scan interpretations patients with acute stroke presenting spoke hospitals between central reading committee neuroradiologists each 2 groups, hospital hub vascular neurologists...
Objective: Evaluate sleep quality, its correlates, and the effect of telephone-based problem-solving treatment (PST) in active duty postdeployment service members with mild traumatic brain injury (mTBI) Setting: Randomized clinical trial. Participants: Active combat-related mTBI. Study design: Education-only (EO) PST groups (N = 178 each) received printed study materials 12 educational brochures. The group additionally up to telephone calls addressing participant-selected issues. Outcomes...
Preclinical Alzheimer disease (AD) trials simultaneously test candidate treatments and the implications of disclosing biomarker information to cognitively unimpaired individuals.
Abstract Introduction The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers as well safety outcomes. We analyzed these data explore relationships between drug exposure and pharmacodynamic effects examine correlations among outcome measures. Methods was multicenter, randomized, placebo-controlled trial two dose regimens placebo administered for 18 months individuals with AD. Changes measures...
Most Alzheimer's disease (AD) clinical trials enroll participants multinationally. Yet, few data exist to guide investigators and sponsors regarding the types of patients enrolled in these studies whether participant characteristics vary by region. We used derived from four multinational phase III mild moderate AD examine regional differences with regard demographics, safety reporting, baseline scores on Mini Mental State Examination (MMSE), 11-item Disease Assessment Scale–Cognitive...